Evidence map›Paper›PMID 32277815›Full record

ArticleClinical infectious diseases : an official publication of the Infectious Diseases Society of America2021

The Clofazimine for Treatment of Cryptosporidiosis in HIV-Infected Adults (CRYPTOFAZ) and Lessons Learned for Anticryptosporidial Drug Development.

Christopher D Huston

Abstract readComment
In one paragraph

Article in Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Article
  2. Frontiers in veterinary science · 2024
    Article
  3. Article
  4. Review
  5. Opportunities and Challenges in Developing aACS infectious diseases · 2021
    Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

1 author.

Christopher D HustonDepartment of Medicine, University of Vermont Larner College of Medicine, Burlington, Vermont, USA.

Funding

Using Dengue Controlled Human Infection Model to Identify Adaptive Immune Correlates of ProtectionP20GM125498 · NIGMS · UNIVERSITY OF VERMONT & ST AGRIC COLLEGE · PI Kristen Pierce · 2018 to 2026
$24.9M
Preclinical optimization of a parasiticidal drug for cryptosporidiosisR01AI143951 · NIAID · UNIVERSITY OF VERMONT & ST AGRIC COLLEGE · PI HUSTON, CHRISTOPHER D, MEYERS, MARVIN J · 2019 to 2023
$3.3M
Novel approaches to develop a treatment for cryptosporidiosisR21AI101381 · NIAID · UNIVERSITY OF VERMONT & ST AGRIC COLLEGE · PI HUSTON, CHRISTOPHER D · 2013 to 2014
$419k
NIAID NIH HHS R01 AI143951NIAID NIH HHS R21 AI101381NIGMS NIH HHS P20 GM125498
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

CryptosporidiosisHIV InfectionsAdultClofazimineDiarrheaDrug DevelopmentHumansClofazimineanticryptosporidialclofaziminecontrolled human infection modelcryptosporidiosiscryptosporidium

Identifiers

PMID32277815
PMCPMC8427724

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.